The primary purpose of the study is to quantify participants' demographic parameters, country standard therapies, treatment patterns and outcomes among participants with chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) in oncology concentration hospitals in Latin America.
This is a retrospective (take a look back at events that already have taken place), non-interventional, multicenter (when more than one hospital or medical school team work on a medical research study) study to review medical records of adult participants with a diagnosis of CLL, MM or NHL anytime since 01 January 2006. Only data available from clinical practice will be collected. All eligible participants at participating centers will be included regardless of participant's demographics, prior or current treatments for disease, or clinical outcome. The period of observation will span from 01 January 2006 through present, but all eligible participants must be followed for a minimum of 1 year, unless the participant died within that first year. Participant demographic parameters, standard therapies, treatment patterns and outcomes will be primarily quantified.
Study Type
OBSERVATIONAL
Enrollment
5,443
This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
Unnamed facility
Buenos Aires, Argentina
Unnamed facility
Córdoba, Argentina
Unnamed facility
La Plata Lpl Lpl, Argentina
Unnamed facility
Belo Horizonte, Brazil
Unnamed facility
Fortaleza, Brazil
Unnamed facility
Goiânia, Brazil
Unnamed facility
Porto Alegre, Brazil
Unnamed facility
São José do Rio Preto, Brazil
Unnamed facility
São Paulo, Brazil
Unnamed facility
Santiago, Chile
...and 13 more locations
Number of Participants with Previous Comorbidities
Comorbidities included: heart, diabetes, hypertension, renal, infections, other neoplasia, neurologic, rheumatologic, HIV, thrombosis, bone and other.
Time frame: 1 year
Number of Participants as per treatment therapy received
Cancer treatment (Chronic Lymphocytic Leukemia \[CLL\], Multiple Myeloma \[MM\] and non-Hodgkin lymphoma \[NHL\]) for all participants is summarized by the number of participants who had any type of surgery or radiotherapy (external radiation or brachytherapy) or other drug treatments.
Time frame: 1 year
Overall survival
Overall Survival (OS) was defined as the time from date of starting treatment to death due to any cause.
Time frame: 1 year
Number of Participants with Response to Treatment
Number of participants who responded to treatment is presented. Treatment response will be assessed based on complete response or partial response.
Time frame: 1 year
Incidence Percentage of Participants with Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and non-Hodgkin lymphoma (NHL)
Incidence of CLL, MM and NHL will be reported. It is a percentage of the population at risk of developing the disease.
Time frame: 1 year
Prevalence Percentage of Participants with CLL, MM and NHL
Prevalence of CLL, MM and NHL will be reported. Prevalence will be estimated using available population demographic information as the denominators and using the percentage of registered participants with those cancers at the sites as the numerators.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.